Menu
Back to Journals » International Journal of General Medicine » Volume 16
Expression of Syndecan-1 and Cyclin D1 in Salivary Gland Tumors in Relation to Clinicopathological Parameters [Erratum]
Authors Mohammad DN, Ibraheem BF , Khudair HH, Mahmood DK
Received 18 July 2023
Accepted for publication 18 July 2023
Published 22 July 2023 Volume 2023:16 Pages 3125—3126
Mohammad DN, Ibraheem BF, Khudair HH, Mahmood DK. Int J Gen Med. 2023;16:823–835.
It has come to our attention that Figure 1 on page 827 is incorrect. An error during the preparation of Figure 1 for publishing led to the inadvertent creation of duplicate features, parts A-F were duplicated from Figure 2A–F. The journal wishes to apologise for this error. The correct version of Figure 1 is as follows.
 |
Figure 1 Continued. |
 |
Figure 1 Syndecan-1 immunoexpression in benign and malignant salivary tumors. (A) Score 3 immunoexpression in ductal and myoepithelial cells of pleomorphic adenoma X40. (B) Mixed intra cellular localization in pleomorphic adenoma X40. (C) Mixed intracellular localization in bilayered epithelia of warthin tumor X40. (D) Score 3 expression and mixed intracellular localization in cribriform adenocystic carcinoma X40. (E) Score 3 immunoexpression and mixed localization of both epidermoid and mucous cells in mucoepidermoid carcinoma X40. (F) Capsular invasion of both acinar and ductal cells in acinic cell carcinoma X10. (G) Muscle invasion of acinar and ductal cells in acinic cell carcinoma X10. |
© 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.